Novo Nordisk's Semaglutide Shows Promise in MASH Phase 3 Study with Regulatory Plans

Novo Nordisk's semaglutide has yielded promising results in the Phase 3 trial for treating metabolic dysfunction-associated steatohepatitis (MASH), indicating significant advancements in liver fibrosis and steatohepatitis resolution. The Essence study demonstrated that 37% of patients on a weekly dose of semaglutide 2.4 mg exhibited improvements in liver fibrosis without worsening steatohepatitis, compared to only 22.5% in the placebo group. Furthermore, the resolution of steatohepatitis was observed in 62.9% of semaglutide users versus 34.1% among those given a placebo. These outcomes pave the way for Novo Nordisk to pursue regulatory approval in the U.S. and Europe by 2025, potentially marking semaglutide as the first GLP-1 receptor agonist approved for this condition[1][2].